UBS Keeps Their Buy Rating on CSL (CMXHF)

UBS analyst Marcus Curley maintained a Buy rating on CSL today and set a price target of A$300.00. The company’s shares closed today at $131.65.

Elevate Your Investing Strategy:

• Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

According to TipRanks, Curley is an analyst with an average return of -10.8% and a 42.39% success rate. Curley covers the Healthcare sector, focusing on stocks such as CSL, Resmed, and Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for CSL with a $179.75 average price target, a 36.54% upside from current levels. In a report released yesterday, CLSA also maintained a Buy rating on the stock with a A$275.00 price target.

CMXHF market cap is currently $66.09B and has a P/E ratio of 20.99.

Based on the recent corporate insider activity of 18 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of CMXHF in relation to earlier this year.